Pathological diagnosis of prostate cancer is usually obtained by a transrectal ultrasound-guided biopsy prompted by elevated levels of serum prostate-specific antigen (PSA) and/or an abnormal digital rectal examination (DRE). This evidence concerns the gene KLK3 and prostate carcinoma.